{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:35:55Z","timestamp":1740137755222,"version":"3.37.3"},"reference-count":38,"publisher":"Georg Thieme Verlag KG","issue":"11","funder":[{"DOI":"10.13039\/501100001822","name":"Austrian Academy of Sciences","doi-asserted-by":"crossref","award":["24693"],"award-info":[{"award-number":["24693"]}],"id":[{"id":"10.13039\/501100001822","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund FWF","doi-asserted-by":"crossref","award":["P22521-B18"],"award-info":[{"award-number":["P22521-B18"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund FWF","doi-asserted-by":"crossref","award":["P26185-B19"],"award-info":[{"award-number":["P26185-B19"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jubil\u00e4umsfonds of the Austrian National Bank","award":["14263"],"award-info":[{"award-number":["14263"]}]},{"name":"DK-MOLIN","award":["FWF\u2013W1241"],"award-info":[{"award-number":["FWF\u2013W1241"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Background\u2003For patients treated with dual antiplatelet therapy, standardized drug-specific 3-to-7 day cessation is recommended prior to major surgery to reach sufficient platelet function recovery. Here we investigated the hypothesis that supplemental fibrinogen might mitigate the inhibitory effects of antiplatelet therapy.<\/jats:p><jats:p>Methods and Results\u2003To this end blood from healthy donors was treated in vitro with platelet inhibitors, and in vitro thrombus formation and platelet activation were assessed. Ticagrelor, acetylsalicylic acid, the combination of both, and tirofiban all markedly attenuated the formation of adherent thrombi, when whole blood was perfused through collagen-coated microchannels at physiological shear rates. Addition of fibrinogen restored in vitro thrombus formation in the presence of antiplatelet drugs and heparin. However, platelet activation, as investigated in assays of P-selectin expression and calcium flux, was not altered by fibrinogen supplementation. Most importantly, fibrinogen was able to restore in vitro thrombogenesis in patients on maintenance dual antiplatelet therapy after percutaneous coronary intervention.<\/jats:p><jats:p>Conclusion\u2003Thus, our in vitro data support the notion that supplementation of fibrinogen influences the perioperative hemostasis in patients undergoing surgery during antiplatelet therapy by promoting thrombogenesis without significantly interfering with platelet activation.<\/jats:p>","DOI":"10.1055\/s-0040-1715445","type":"journal-article","created":{"date-parts":[[2020,8,9]],"date-time":"2020-08-09T22:34:31Z","timestamp":1597012471000},"page":"1548-1556","source":"Crossref","is-referenced-by-count":2,"title":["Supplemental Fibrinogen Restores Platelet Inhibitor-Induced Reduction in Thrombus Formation without Altering Platelet Function: An In Vitro Study"],"prefix":"10.1055","volume":"120","author":[{"given":"Thomas","family":"B\u00e4rnthaler","sequence":"additional","affiliation":[{"name":"Otto Loewi Research Center, Division of Pharmacology Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Mahla","sequence":"additional","affiliation":[{"name":"Division of Anaesthesiology for Cardiovascular and Thoracic Surgery and Intensive Care Medicine, Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabor G.","family":"Toth","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rufina","family":"Schuligoi","sequence":"additional","affiliation":[{"name":"Otto Loewi Research Center, Division of Pharmacology Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Pr\u00fcller","sequence":"additional","affiliation":[{"name":"Clinical Institute of Medical Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Buschmann","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akos","family":"Heinemann","sequence":"additional","affiliation":[{"name":"Otto Loewi Research Center, Division of Pharmacology Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,8,9]]},"reference":[{"issue":"08","key":"ref1","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1538-7836.2012.04793.x","article-title":"Mechanisms and monitoring of bypassing agent therapy","volume":"10","author":"M Hoffman","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"L Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"20","key":"ref3","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"S D Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.athoracsur.2019.01.086","article-title":"Bleeding in patients treated with ticagrelor or clopidogrel before coronary artery bypass grafting","volume":"107","author":"M Holm","year":"2019","journal-title":"Ann Thorac Surg"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"M Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/ehjqcco\/qcy027","article-title":"Variation in preoperative antithrombotic strategy, severe bleeding, and use of blood products in coronary artery bypass grafting: results from the multicentre E-CABG registry","volume":"4","author":"F Biancari","year":"2018","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/eurheartj\/ehv381","article-title":"Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study","volume":"37","author":"E C Hansson","year":"2016","journal-title":"Eur Heart J"},{"issue":"06","key":"ref8","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.athoracsur.2016.05.003","article-title":"Does platelet reactivity predict bleeding in patients needing urgent coronary artery bypass grafting during dual antiplatelet therapy?","volume":"102","author":"E Mahla","year":"2016","journal-title":"Ann Thorac Surg"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"e002786","DOI":"10.1161\/CIRCINTERVENTIONS.115.002786","article-title":"Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study","volume":"8","author":"S A O'Connor","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1111\/jth.13511","article-title":"Effects of autologous platelet transfusion on platelet inhibition in ticagrelor-treated and clopidogrel-treated subjects","volume":"14","author":"R Teng","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1055\/s-0038-1673381","article-title":"In vitro reversal of the anti-aggregant effect of ticagrelor using untreated platelets","volume":"118","author":"P C Kruger","year":"2018","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref12","doi-asserted-by":"crossref","first-page":"e005120","DOI":"10.1161\/CIRCINTERVENTIONS.117.005120","article-title":"Impact of timing on the functional recovery achieved with platelet supplementation after treatment with ticagrelor","volume":"10","author":"M U Zafar","year":"2017","journal-title":"Circ Cardiovasc Interv"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/bja\/aei160","article-title":"Effect of fibrinogen on reversal of dilutional coagulopathy: a porcine model","volume":"95","author":"D Fries","year":"2005","journal-title":"Br J Anaesth"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1213\/ane.0b013e3181966675","article-title":"The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia","volume":"108","author":"T Lang","year":"2009","journal-title":"Anesth Analg"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1213\/ANE.0000000000003508","article-title":"Fibrinogen concentrate in cardiovascular surgery: a meta-analysis of randomized controlled trials","volume":"127","author":"J Y Li","year":"2018","journal-title":"Anesth Analg"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1053\/j.jvca.2015.02.023","article-title":"Thresholds for perioperative administration of hemostatic blood components and coagulation factor concentrates: an unmet medical need","volume":"29","author":"D Bolliger","year":"2015","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"05","key":"ref17","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/trf.12431","article-title":"Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy","volume":"54","author":"J H Levy","year":"2014","journal-title":"Transfusion"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000437143","article-title":"The EP3 agonist sulprostone enhances platelet adhesion but not thrombus formation under flow conditions","volume":"96","author":"L Pasterk","year":"2015","journal-title":"Pharmacology"},{"issue":"08","key":"ref19","doi-asserted-by":"crossref","first-page":"e40222","DOI":"10.1371\/journal.pone.0040222","article-title":"Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation","volume":"7","author":"S Philipose","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1161\/ATVBAHA.110.216374","article-title":"The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation","volume":"30","author":"S Philipose","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.thromres.2016.09.002","article-title":"Plasminogen activator inhibitor type 1 in platelets induces thrombogenicity by increasing thrombolysis resistance under shear stress in an in-vitro flow chamber model","volume":"146","author":"K Hosokawa","year":"2016","journal-title":"Thromb Res"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1111\/jth.13870","article-title":"Implementation of buffy-coat-derived pooled platelet concentrates for internal quality control of light transmission aggregometry: a proof of concept study","volume":"15","author":"F Pr\u00fcller","year":"2017","journal-title":"J Thromb Haemost"},{"volume-title":"Platelets. 2nd ed","year":"2007","author":"A D Michelson","key":"ref23"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCULATIONAHA.109.853085","article-title":"Combination antithrombotic therapies","volume":"121","author":"P A Gurbel","year":"2010","journal-title":"Circulation"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1177\/000331978303401101","article-title":"Plasma fibrinogen levels and the clinical course of acute myocardial infarction","volume":"34","author":"N Cristal","year":"1983","journal-title":"Angiology"},{"issue":"21","key":"ref26","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction","volume":"338","year":"1998","journal-title":"N Engl J Med"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1053\/j.jvca.2014.12.010","article-title":"Efficacy of fibrinogen concentrate compared with cryoprecipitate for reversal of the antiplatelet effect of clopidogrel in an in vitro model, as assessed by multiple electrode platelet aggregometry, thromboelastometry, and modified thromboelastography","volume":"29","author":"B L Cartwright","year":"2015","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/bja\/aew315","article-title":"Fibrinogen supplementation ex vivo increasesclot firmness comparable to platelet transfusion in thrombocytopenia","volume":"117","author":"B Schenk","year":"2016","journal-title":"Br J Anaesth"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/bja\/aew169","article-title":"Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy","volume":"117","author":"N Rahe-Meyer","year":"2016","journal-title":"Br J Anaesth"},{"issue":"06","key":"ref30","doi-asserted-by":"crossref","first-page":"e002066","DOI":"10.1161\/JAHA.115.002066","article-title":"Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery","volume":"4","author":"M Ranucci","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"07","key":"ref31","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1001\/jama.2016.21037","article-title":"Effect of fibrinogen concentrate on intraoperative blood loss among patients with intraoperative bleeding during high-risk cardiac surgery: a randomized clinical trial","volume":"317","author":"S Bilecen","year":"2017","journal-title":"JAMA"},{"issue":"04","key":"ref32","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/bja\/aew300","article-title":"When more is less efficacious: fibrinogen concentrate in complex cardiac surgery","volume":"117","author":"A K Davis","year":"2016","journal-title":"Br J Anaesth"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1515\/cclm-2015-0345","article-title":"Comparison of functional fibrinogen (FF\/CFF) and FIBTEM in surgical patients - a retrospective study","volume":"54","author":"F Pr\u00fcller","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"22","key":"ref34","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2015-01-622928","article-title":"Structural and functional characterization of a specific antidote for ticagrelor","volume":"125","author":"A Buchanan","year":"2015","journal-title":"Blood"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1160\/TH12-06-0441","article-title":"Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions","volume":"109","author":"K Hosokawa","year":"2013","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref36","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/bja\/aet229","article-title":"Haemodilution-induced changes in coagulation and effects of haemostatic components under flow conditions","volume":"111","author":"S Ogawa","year":"2013","journal-title":"Br J Anaesth"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"e86491","DOI":"10.1371\/journal.pone.0086491","article-title":"Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model","volume":"9","author":"K Hosokawa","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"ref38","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1055\/s-0039-1693411","article-title":"Total Thrombus-Formation Analysis System (T-TAS): clinical application of quantitative analysis of thrombus formation in cardiovascular disease","volume":"119","author":"K Kaikita","year":"2019","journal-title":"Thromb Haemost"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1715445.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T09:26:56Z","timestamp":1667726816000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1715445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,9]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,8]]},"published-print":{"date-parts":[[2020,11]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1715445","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"type":"print","value":"0340-6245"},{"type":"electronic","value":"2567-689X"}],"subject":[],"published":{"date-parts":[[2020,8,9]]}}}